DBVT News and Press, DBV Technologies S.A. From 02/27/23

Montrouge, France, February 27, 2023 DBV Technologies to Report Full Year 202 2 Financial Results and Business Updates on March 2 , 202 3 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharma...

Montrouge, France, February 21, 2023 DBV Technologies to Participate in Upcoming AAAAI 2023 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at t...

Montrouge, France, February 10, 2023 DBV Technologies t o Participate i n Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its parti...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of Dec em ber 3 1 , 202 2 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Mark...

Summary I explain why I've added Organigram to my tax loss selling basket. I also review the company's performance and risks. Finally, I recap my entire 2022 tax loss selling basket of stocks, some of which I didn't have time to write up individually. Tax Loss Selling Strategy...

DBV Technologies ( NASDAQ: DBVT ) ( OTC:DBVTF ) said the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold on its phase 3 trial which will evaluate the modified Viaskin Peanut 250 μg patch (DBV712) to treat children aged four years to seven years w...

Montrouge, France, December 23, 2022 DB V Technologies Announces FDA H as Lift ed Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial DBV expects to initiate patient screening in Q1 2023 with the last patient screened by 1H 2024 a...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 3 0 Novem bre 202 2 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place...

Montrouge, France, November 9, 2022 DB V Technologies to Highlight New Clinical Data at ACAAI 2022 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that ...